Depot and Extended-Release Formulations

Quick overview

Many natural peptides are cleared from the body in minutes. A depot (or extended-release) formulation is a product built so that a peptide drug leaves the injection site slowly, over days, weeks or months. The goal is to keep exposure steadier and to reduce how often a medicine must be given. [1]

This page is science education. It describes how approved products are designed and what regulators' labels say. It does not describe how to prepare or give any product, and it is not advice to start, stop or change a medicine.

Evidence labels used here: approved medicine (named regulator and product) and promising but limited where a source describes only design studies.

Why peptides need help to last

Reviews describe the problem plainly: peptides have short half-lives because of metabolism by peptide-cutting enzymes, and they can be physically and chemically fragile. [2] Another review adds that fast kidney clearance is a common cause of short half-lives. [3] A depot attacks the problem from the formulation side. The molecule is the same, but the product around it controls the release.

How a depot works

In the long-acting products that are in clinical use, a peptide is typically held inside tiny particles of a slowly dissolving polymer such as polylactide-co-glycolide (PLGA) or polylactic acid. The particles are made by methods such as double emulsion, coacervation or spray drying. [1] The same review notes that polymer properties and even minor manufacturing changes can alter the release profile, particle size and how much drug is captured. It also notes that the peptide can be stressed by solvents, shear and temperature during manufacture. [1]

A second review of the field stresses that manufacturing challenges and critical quality attributes are essential to both activity and safety for sustained-release peptides. [2] In plain terms, two depots with the same peptide are not automatically the same medicine.

Worked example: a leuprolide depot label

Leuprolide acetate is a peptide that acts on the pituitary gland. The US label for Lupron Depot (AbbVie, DailyMed version published 2026-06-18) lists products containing microspheres of leuprolide acetate in a biodegradable lactic acid/glycolic acid polymer, supplied for administration every month, every 3 months or every 4 months depending on the product. [4] The label also warns that fractional doses or combinations of depot doses must not be used because of different release characteristics. [4] That sentence shows why a depot cannot be treated as a simple "amount of drug."

Two features of the label's pharmacology are worth noticing:

• Blood levels rise sharply after injection and then fall. For the 3-month product the label reports a mean peak of 48.9 ng/mL at 4 hours that declined to 0.67 ng/mL at 12 weeks, with steady concentrations through the interval after the third week. [4]
• The label also says leuprolide acetate is not active when given orally, which is one reason an injectable depot is used. [4]

What trials of depots measure

Studies of depot leuprolide usually report a hormone measurement. A phase 3 open-label study of a 6-month leuprolide mesylate depot in 137 men with advanced prostate cancer reported that 98.5% reached a castrate testosterone level by Day 28; hot flush (48.9%) and hypertension (14.6%) were the most common adverse events. [5] An earlier phase 1 study of a 3-month depot found testosterone suppression to the castration range for at least 13 weeks. [6] Both were open-label studies without a comparison group, and testosterone is a biomarker, not a measure of how patients feel or live. See Pharmacokinetics vs Clinical Effectiveness for why that distinction matters.

Depot, brand, molecule: keep them apart

A depot product is a formulation, with its own approval, its own label and its own release behavior. It is not the same thing as the peptide it contains. This is the same idea explained in Active Ingredient, Brand, Formulation and Indication.

Related guides

• Subcutaneous Delivery: The Science
• Lipidation, PEGylation and Cyclization, a molecular route to longer action
• Endocrine and Reproductive Peptide Medicines